Dr. Sharma on PD-L1 as Biomarker for Immunotherapy in Bladder Cancer

Partner | Cancer Centers | <b>MD Anderson</b>

Padmanee Sharma, MD, PhD, professor of Immunology, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses PD-L1 as a predictive biomarker for immunotherapy in patients with bladder cancer.

Padmanee Sharma, MD, PhD, professor of Immunology, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses PD-L1 as a predictive biomarker for immunotherapy in patients with bladder cancer.

PD-L1 as a biomarker is generating much excitement in the field of bladder cancer, as anti—PD-1/PD-L1 agents have demonstrated promise in these patients, Sharma explains.

However, Sharma cautions that PD-L1 may not be the most accurate and predictive biomarker, as it changes over time and does not present a clear picture of the evolving immune response. Other biomarkers, including CD8 T cells, CD45RA cells, and Granzyme B may be worth investigating, she adds.